Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Wouter W. de Herder(Erasmus University Rotterdam), Jaap J.M. Teunissen(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), Boen L.R. Kam(Erasmus MC), Martijn van Essen(Erasmus MC), Marion de Jong(Shell (Netherlands)), Roelf Valkema(Active Medicine (United Kingdom))
Cited by 462
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914